Search ARM

OmniSpirant Limited is an early stage therapeutics company based in Ireland developing a novel platform technology based on inhaled stem cell exosomes for treating respiratory diseases. The proprietary platform technology is based on bioengineered and surface engineered allogeneic stem cell exosomes delivered by inhalation.

Lung diseases have a severely unmet patient need and are forecast to kill one in five people globally, OmniSpirant’s therapeutic programs can provide a desperately needed breakthrough in the field of respiratory medicine with transformational potential for Cystic Fibrosis (OS001) and COPD and ARDS patients (OS002). Each of these disease indications and the proposed breakthrough treatments have the combined potential to positively impact millions of patients’ lives.

Contact OmniSpirant Limited
Visit Website